Ranbaxy recalls atorvastatin calcium tablets in 10-, 20-, 40-mg dosages
November 26th 2012More than 40 lots of atorvastatin calcium tablets, the generic version of Pfizer?s Lipitor, are being recalled by Ranbaxy Pharmaceuticals Inc. (RPI) because they may contain glass particles that are estimated to be less than 1 mm in size, according to Ranbaxy's website.
Best tocolytic therapy options outlined for preterm delivery
November 20th 2012Prostaglandin inhibitors and calcium channel blockers were ranked as the top tocolytic therapy options in terms of outcomes of 48-hour delay in delivery, neonatal mortality, respiratory distress syndrome, and maternal side effects, according to a systematic review and network meta-analysis published Oct. 9 in BMJ.
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
November 19th 2012Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
November 16th 2012Adding aliskiren to standard therapy with renin-angiotensin system blockade could be harmful and did not lower the risk of cardiovascular and renal adverse events when used in patients with type 2 diabetes at risk for these events, according to an online study in the New England Journal of Medicine.
NACDS Foundation supports Million Hearts initiative
November 9th 2012Thousands of patients who attended one of 65 health fairs held throughout the United States were educated about the ABCS of heart health, thanks to $35,000 in grant money from the National Association of Chain Drug Stores (NACDS) Foundation.
Mass. Board of Pharmacy director fired for not investigating complaint about NECC
November 8th 2012James D. Coffey, RPh, director of the Massachusetts Board of Registration in Pharmacy, has been removed from his position after allegedly failing to follow up on a complaint about the New England Compounding Pharmacy (NECC) from the Colorado Board of Pharmacy in July.